|
[1]PARK SA, JEONG MS, HA KT, et al.Structure and function of vascular endothelial growth factor and its receptor system[J].BMB Rep, 2018, 51 (2) :73-78.
|
|
[2]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.
|
|
[3]SHIBUYA M, YAMAGUCHI S, YAMANE A, et al.Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family[J].Oncogene, 1990, 5 (4) :519-524.
|
|
[4]de VRIES C, ESCOBEDO JA, HOUCK K, et al.The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor[J].Science, 1992, 255 (5047) :989-991.
|
|
[5]ZHANG J, JIANG X, JIANG Y, et al.Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors asanticancer drugs[J].Eur J Med Chem, 2016, 108:495-504.
|
|
[6]ROSKOSKI R Jr.Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas[J].Pharmacol Res, 2017, 120:116-132.
|
|
[7]LEE SY, OH SC.Changing strategies for target therapy in gastric cancer[J].World J Gastroenterol, 2016, 22 (3) :1179-1189.
|
|
[8]HU YL, SUN DW, LUO FX, et al.Influencing factors for microvascular invasion in patients with single hepatocellular carcinoma and their prognosis[J].J Clin Hepatol, 2018, 34 (9) :1911-1916. (in Chinese) 胡月雷, 孙大伟, 骆飞翔, 等.单发肝细胞癌发生微血管侵犯的影响因素及预后分析[J].临床肝胆病杂志, 2018, 34 (9) :1911-1916.
|
|
[9]EICHMANN A, SIMONS M.VEGF signaling inside vascular endothelial cells and beyond[J].Curr Opin Cell Biol, 2012, 24 (2) :188-193.
|
|
[10]TAKAHASHI T, YAMAGUCHI S, CHIDA K, et al.A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells[J].EMBO J, 2001, 20 (11) :2768-2778.
|
|
[11]PENG S, WANG Y, PENG H, et al.Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma[J].Hepatology, 2014, 60 (4) :1264-1277.
|
|
[12]CHEN B, LIU J, WANG X, et al.Co-expression of PDGF-Band VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy[J].Clin Res Hepatol Gastroenterol, 2018, 42 (2) :126-133.
|
|
[13]CAI H, SAIYIN H, LIU X, et al.Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma[J].Mol Oncol, 2018, 12 (12) :2042-2054.
|
|
[14]LI T, ZHU Y, HAN L, et al.VEGFR-1 activation-induced MMP-9-dependent invasion in hepatocellular carcinoma[J].Future Oncol, 2015, 11 (23) :3143-3157.
|
|
[15]MENG J, LIU Y, HAN J, et al.Hsp90βpromoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma[J].Mol Cancer, 2017, 16 (1) :72.
|
|
[16]GHOSH A, DASGUPTA D, GHOSH A, et al.MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2[J].Cell Death Dis, 2017, 8 (3) :e2706.
|
|
[17]WANG L, TONG D, GUO Q, et al.HOXD3 targeted by miR-203a suppresses cell metastasis and angiogenesis through VEGFR in human hepatocellular carcinoma cells[J].Sci Rep, 2018, 8 (1) :2431.
|
|
[18]FU H, ZHANG J, PAN T, et al.miR-378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβand c-Raf[J].Mol Med Rep, 2018, 17 (3) :4581-4588.
|
|
[19]SPALLANZANI A, ORSI G, ANDRIKOU K, et al.Lenvatinib as a therapy for unresectable hepatocellular carcinoma[J].Expert Rev Anticancer Ther, 2018, 18 (11) :1069-1076.
|
|
[20]NEGRI FV, DAL BELLO B, PORTA C, et al.Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment[J].Liver Int, 2015, 35 (8) :2001-2008.
|
|
[21]KUDO M, FINN RS, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J].Lancet, 2018, 391 (10126) :1163-1173.
|
|
[22]KELLEY RK, VERSLYPE C, COHN AL, et al.Cabozantinib in hepatocellular carcinoma:Results of a phase 2 placebo-controlled randomized discontinuation study[J].Ann Oncol, 2017, 28 (3) :528-534.
|
|
[23]SAMAD NA, ABDUL AB, RAHMAN HS, et al.Zerumbone suppresses angiogenesis in HepG2 cells through inhibition of matrix metalloproteinase-9, vascular endothelial growth factor, and vascular endothelial growth factor receptor expressions[J].Pharmacogn Mag, 2018, 13 (4) :s731-s736.
|
|
[24]LEE WS, PYUN BJ, KIM SW, et al.TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis[J].MAbs, 2015, 7 (5) :957-968.
|
|
[25]WANG Y, YAN Z, HUANG Y, et al.Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma[J].Am J Cancer Res, 2017, 7 (3) :603-609.
|
|
[26]HUANG J, TANG Q, WANG C, et al.Molecularly targeted therapy of human hepatocellular carcinoma xenografts with radio-iodinated Anti-VEGFR2 murine-human chimeric Fab[J].Sci Rep, 2015, 5:10660.
|
DownLoad: